Cargando…

Ceramide as a Mediator of Non-Alcoholic Fatty Liver Disease and Associated Atherosclerosis

Cardiovascular disease (CVD) is a serious comorbidity in nonalcoholic fatty liver disease (NAFLD). Since plasma ceramides are increased in NAFLD and sphingomyelin, a ceramide metabolite, is an independent risk factor for CVD, the role of ceramides in dyslipidemia was assessed using LDLR-/- mice, a d...

Descripción completa

Detalles Bibliográficos
Autores principales:	Kasumov, Takhar, Li, Ling, Li, Min, Gulshan, Kailash, Kirwan, John P., Liu, Xiuli, Previs, Stephen, Willard, Belinda, Smith, Jonathan D., McCullough, Arthur
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Public Library of Science 2015
Materias:	Research Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4439060/ https://www.ncbi.nlm.nih.gov/pubmed/25993337 http://dx.doi.org/10.1371/journal.pone.0126910

Ejemplares similares

Turnover of histones and histone variants in postnatal rat brain: effects of alcohol exposure
por: Rachdaoui, Nadia, et al.
Publicado: (2017)

Relationship between hepatic and mitochondrial ceramides: a novel in vivo method to track ceramide synthesis
por: Mucinski, Justine M., et al.
Publicado: (2023)

Plasma Ceramides Are Elevated in Obese Subjects With Type 2 Diabetes and Correlate With the Severity of Insulin Resistance
por: Haus, Jacob M., et al.
Publicado: (2009)

Roles of Ceramides in Non-Alcoholic Fatty Liver Disease
por: Hajduch, Eric, et al.
Publicado: (2021)

Involvement of Ceramides in Non-Alcoholic Fatty Liver Disease (NAFLD) Atherosclerosis (ATS) Development: Mechanisms and Therapeutic Targets
por: Tanase, Daniela Maria, et al.
Publicado: (2021)

Current Modalities of Fibrosis Assessment in Non-alcoholic Fatty Liver Disease
por: Cheah, Mark CC, et al.
Publicado: (2017)

Diagnosis and Management of Alcoholic Liver Disease
por: Dugum, Mohannad, et al.
Publicado: (2015)

Association of non-alcoholic fatty liver disease and polycystic ovarian syndrome
por: Asfari, Mohammad Maysara, et al.
Publicado: (2020)

Sphingolipids in Non-Alcoholic Fatty Liver Disease and Hepatocellular Carcinoma: Ceramide Turnover
por: Simon, Jorge, et al.
Publicado: (2019)

Lipocalin‐2 Protects Against Diet‐Induced Nonalcoholic Fatty Liver Disease by Targeting Hepatocytes
por: Xu, Yanyong, et al.
Publicado: (2019)

Inhibiting Ceramide Synthesis Attenuates Hepatic Steatosis and Fibrosis in Rats With Non-alcoholic Fatty Liver Disease
por: Jiang, Meng, et al.
Publicado: (2019)

Role of ceramide-to-dihydroceramide ratios for insulin resistance and non-alcoholic fatty liver disease in humans
por: Apostolopoulou, Maria, et al.
Publicado: (2020)

Isotope Fractionation during Gas Chromatography Can Enhance Mass Spectrometry-Based Measures of (2)H-Labeling of Small Molecules
por: Downes, Daniel P., et al.
Publicado: (2020)

Hepatic Huwe1 loss protects mice from non-alcoholic fatty liver disease through lipid metabolic rewiring
por: Feng, William W., et al.
Publicado: (2023)

Early-stage non-alcoholic fatty liver disease in relation to atherosclerosis and inflammation
por: Tan, Si-hua, et al.
Publicado: (2023)

Fenretinide inhibits obesity and fatty liver disease but induces Smpd3 to increase serum ceramides and worsen atherosclerosis in LDLR(−/−) mice
por: Thompson, Dawn, et al.
Publicado: (2023)

Clinical spectrum of non-alcoholic fatty liver disease in diabetic and non-diabetic patients()
por: Goh, George Boon-Bee, et al.
Publicado: (2014)

The therapeutic efficacy of intensive medical therapy in ameliorating high-density lipoprotein dysfunction in subjects with type two diabetes
por: Kashyap, Sangeeta, et al.
Publicado: (2016)

Erratum to: The therapeutic efficacy of intensive medical therapy in ameliorating high-density lipoprotein dysfunction in subjects with type two diabetes
por: Kashyap, Sangeeta, et al.
Publicado: (2016)

Assessment of plasma ceramides as predictor for subclinical atherosclerosis
por: Mishra, Pashupati P., et al.
Publicado: (2021)

Endothelial dysfunction and carotid atherosclerosis in non-alcoholic fatty liver disease
por: Dogru, Teoman, et al.
Publicado: (2014)

Plasma Krebs Cycle Intermediates in Nonalcoholic Fatty Liver Disease
por: Sandlers, Yana, et al.
Publicado: (2020)

Association of non-alcoholic fatty liver disease with cardiovascular disease and subclinical atherosclerosis
por: Sao, Rahul, et al.
Publicado: (2017)

Insights into the roles and pathomechanisms of ceramide and sphigosine-1-phosphate in nonalcoholic fatty liver disease
por: Zhu, Cheng, et al.
Publicado: (2023)

Plasma Ceramides Target Skeletal Muscle in Type 2 Diabetes
por: Kirwan, John P.
Publicado: (2013)

Differential role of MLKL in alcohol-associated and non–alcohol-associated fatty liver diseases in mice and humans
por: Miyata, Tatsunori, et al.
Publicado: (2021)

Differential role of MLKL in alcohol-associated and non–alcohol-associated fatty liver diseases in mice and humans
por: Miyata, Tatsunori, et al.
Publicado: (2022)

Increased serum concentration of ceramides in obese children with nonalcoholic fatty liver disease
por: Wasilewska, Natalia, et al.
Publicado: (2018)

Cholesterol-Induced Non-Alcoholic Fatty Liver Disease and Atherosclerosis Aggravated by Systemic Inflammation
por: Kim, Eung Ju, et al.
Publicado: (2014)

Oxidized Lipids: Common Immunogenic Drivers of Non-Alcoholic Fatty Liver Disease and Atherosclerosis
por: Hoebinger, Constanze, et al.
Publicado: (2022)

Obstructive Sleep Apnea Is Associated with Liver Damage and Atherosclerosis in Patients with Non-Alcoholic Fatty Liver Disease
por: Petta, Salvatore, et al.
Publicado: (2015)

Early Pro-Inflammatory Remodeling of HDL Proteome in a Model of Diet-Induced Obesity: (2)H(2)O-Metabolic Labeling-Based Kinetic Approach
por: Sadana, Prabodh, et al.
Publicado: (2020)

Sphingolipids and Atherosclerosis: The Dual Role of Ceramide and Sphingosine-1-Phosphate
por: Piccoli, Marco, et al.
Publicado: (2023)

CML/RAGE Signal Bridges a Common Pathogenesis Between Atherosclerosis and Non-alcoholic Fatty Liver
por: Pang, Qiwen, et al.
Publicado: (2020)

Apigenin attenuates atherosclerosis and non-alcoholic fatty liver disease through inhibition of NLRP3 inflammasome in mice
por: Lu, Zheng, et al.
Publicado: (2023)

A New Targeted Lipidomics Approach Reveals Lipid Droplets in Liver, Muscle and Heart as a Repository for Diacylglycerol and Ceramide Species in Non-Alcoholic Fatty Liver
por: Preuss, Christina, et al.
Publicado: (2019)

Hepatocellular carcinoma in nonalcoholic fatty liver disease with or without cirrhosis: a population-based study
por: Pinyopornpanish, Kanokwan, et al.
Publicado: (2021)

PNPLA3 GG Genotype and Carotid Atherosclerosis in Patients with Non-Alcoholic Fatty Liver Disease
por: Petta, Salvatore, et al.
Publicado: (2013)

Is There an Association of Vascular Disease and Atherosclerosis in Children and Adolescents With Obesity and Non-alcoholic Fatty Liver Disease?
por: Karjoo, Sara
Publicado: (2018)

Fatty acid transport protein 2 interacts with ceramide synthase 2 to promote ceramide synthesis
por: Kim, Jiyoon L., et al.
Publicado: (2022)

Cannot write session to /tmp/vufind_sessions/sess_q2fosl5s9l4hn28jk07cjma8ai